Economics of Cancer

"There is nothing else in the health-care field that can do
what a good prescription drug can do--on the money side.
It is a business to be envied by all." --New York Times, July 28, 1989

Economics, as much as medical science, drives the direction of cancer research and treatment. This thesis, which was controversial when I first stated it in The Cancer Syndrome, has since become commonplace, and hardly worth arguing.

One of the reasons I started The Cancer Chronicles, however, was to provide a kind of running commentary, an instant update, on the link between business and cancer. Here are ten articles from The Cancer Chronicles on how economics and cancer interact:

  • Mergermania (1989)
  • Cancer Market Booms (1990)
  • Fierce Competition (1990)
  • FDA and IL-12 (1992)
  • Drug 'Majors' (1993)
  • Asian Herb Market (1994)
  • Medimmune's Plunge (1994)
  • NCI-BMS Taxol Deal (1994)
  • Pharmacia and Upjohn Merge (1995)
  • CA Hospitals Organize (1995)
  • Right Heart Catheterization (1997)

    • Ralph W. Moss, Ph.D. is the author of many books and documentaries on cancer-related topics. He has been an advisor on alternative cancer treatments to the National Institutes of Health, Columbia University, and the University of Texas. He researches and writes The Moss Reports on cancer. For information, please contact coordinator Anne Beattie @ 144 St. John's Place, Brooklyn, NY 11217; Phone 718-636-4433; Fax 718-636-0186.


    Return Home